Trial reportBone marrow transplantation2009
Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients.
Trial report in Bone marrow transplantation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Treatment for osteoporosis in people with beta-thalassaemia.The Cochrane database of systematic reviews · 2023Pooled it
- Prevention and treatment of bone loss and fractures in patients undergoing a hematopoietic stem cell transplant: a systematic review and meta-analysis.Bone marrow transplantation · 2017Pooled it
- An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial.Bone marrow transplantation · 2017Trial
- Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-versus-Host Disease Survivorship after Hematopoietic Cell Transplantation: Part III. Long-Term Impact of Chronic Graft-versus-Host Disease on Endocrinologic, Cardiovascular, and Metabolic Outcomes in Survivors of Pediatric Hematopoietic Cell Transplantation.Transplantation and cellular therapy · 2025Article
- Randomized controlled trial of pre-transplant zoledronate versus observation for prevention of bone loss in allogeneic hematopoietic cell transplantation.Blood cell therapy · 2024Article
- A Novel Germline Mutation ofInternational journal of molecular sciences · 2021Article
- Osteoporosis management in hematologic stem cell transplant recipients: Executive summary.Journal of bone oncology · 2021Review
- Bone turnover markers as an aid to monitor osteoporosis following allogeneic hematopoietic stem cell transplantation.Annals of hematology · 2020Observational
- Bone management in hematologic stem cell transplant recipients.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018Review
- Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Article
- Factors influencing the late phase of recovery after bone mineral density loss in allogeneic stem cell transplantation survivors.Bone marrow transplantation · 2016Article
- Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial.BoneKEy reports · 2016Article
- Osteoporosis after stem cell transplantation.Current osteoporosis reports · 2013Review
- Changes in biomarkers of bone resorption over the first six months after pediatric hematopoietic cell transplantation.Pediatric transplantation · 2012Article
- Bone loss after allogeneic haematopoietic stem cell transplantation: a pilot study on the use of zoledronic Acid.Chemotherapy research and practice · 2012Article
- Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients.Bone marrow transplantation · 2011Review
- Skeletal integrity and visceral transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2010Article
- Bone mineral density after bone marrow transplantation in childhood: measurement and associations.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2010Article
- Cancer therapies and bone health.Current rheumatology reports · 2010Review
- Quantitative ultrasound detects bone changes following bone marrow transplantation in pediatric subjects with hematological diseases: a longitudinal study.Journal of endocrinological investigationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone loss is recognized as worsening the quality of life in long-term survivors of Allo-SCT. This study evaluated the risk factors associated with bone loss and the role of zoledronic acid in preventing bone loss in allogeneic recipients. Fifty-three patients who underwent HLA-matched Allo-SCT were evaluated for their bone mineral density (BMD) in the lumbar spine and femoral neck at regular intervals. Zoledronic acid (4 mg) was given i.v. to 18 patients (ZA patients) at 2 months after SCT and then every 3 months until 2 years. Grade 2-4 acute GVHD was associated with bone loss (odds ratio (OR)=4.90, 95% confidence interval (CI)=1.41-16.99; P=0.012) at 1 year after SCT, whereas extensive chronic GVHD and steroid use were both unfavorable prognostic factors (OR=9.00 and 7.22, 95% CI=1.52-53.40 and 1.44-36.22; P=0.016, respectively) in terms of osteopenia/osteoporosis at 2 years after transplantation. The use of zoledronic acid significantly prevented bone loss in the femoral neck as well as the spine (OR=0.18, 95% CI=0.05-0.69, P=0.012). Therefore, BMD measurements and the use of zoledronic acid are recommended in cases of GVHD or long-term steroid use after Allo-SCT to prevent bone loss and threatening skeletal events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.